Relationship between fibrinolytic and metabolic variables: a study in patients attending a lipid clinic

References

• Collen D, Lijnen H R. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114–24
   PubMed Web of Science ®Google Scholar
• Ridker P M. Fibrinolytic and inflammatory markers for arterial occlusion: the evolving epidemiology of thrombosis and haemostasis. Thromb Haemost 1997; 78: 53–9
   PubMed Web of Science ®Google Scholar
• Hamsten A, Eriksson P. Fibrinolysis and atherosclerosis. Baillieres Clin Haematol 1995; 8: 345–63
   PubMedGoogle Scholar
• Wiman B. Plasminogen activator inhibitor-1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost 1995; 74: 71–6
   PubMed Web of Science ®Google Scholar
• Emeis J J, Verheijen J H, Ronday H K, deMaat M PM, Brakman P. Progress in clinical fibrinolysis. Fibrinolysis Proteolysis 1997; 11: 67–84
   Google Scholar
• Juhan-Vague I, Alessi M C. Fibrinolysis and risk of coronary artery disease. Fibrinolysis 1996; 10: 127–36
   Google Scholar
• Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3–9
   PubMed Web of Science ®Google Scholar
• Panahloo A, Yudkin J S. Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease. J Cardiovasc Risk 1997; 4: 91–9
   PubMedGoogle Scholar
• Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 1992; 12: 19–27
   PubMedGoogle Scholar
• Juhan-Vague I, Alessi M C. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656–60
   PubMed Web of Science ®Google Scholar
• Gough S CL, Juhan-Vague I. Insulin resistance and alterations in the fibrinolytic system. Cardiovasc Risk Factor 1993; 3: 387–96
   Google Scholar
• Schneider D J, Nordt T K, Sobel B E. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993; 42: 1–7
   PubMed Web of Science ®Google Scholar
• McGill J B, Schneider D J, Arfken C L, Lucore C L, Sobel B E. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43: 104–9
   PubMed Web of Science ®Google Scholar
• Potter van Loon B J, Kluft C, Radder J K, Blankenstein M A, Meinders A E. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993; 42: 945–9
   PubMed Web of Science ®Google Scholar
• Pananhloo A, Mohamed-Ali V, Lane A, Green F, Humphries S E, Yudkin J S. Determinants of plasminogen activator inhibitor 1 activity in treated NJDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44: 37–42
   PubMed Web of Science ®Google Scholar
• Gray R P, Mohamed-Ali V, Patterson D HL, Yudkin J S. Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction. Thromb Haemost 1995; 73: 261–7
   PubMed Web of Science ®Google Scholar
• Byberg L, Siegbahn A, Berglund L, McKeigue P, Reneland R, Lithell H. Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. Arterioscler Thromb Vasc Biol 1998; 18: 258–64
   PubMed Web of Science ®Google Scholar
• Carlson-Asplund A, Hamsten A, Wiman B, Carlson L A. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo and hypertriglyceridaemic men. Diabetologia 1993; 36: 817–25
   PubMed Web of Science ®Google Scholar
• Mykkanen L, Rönnemaa T, Marniemi J, Haffner S M, Bergman R, Laakso M. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1994; 14: 1264–71
   PubMed Web of Science ®Google Scholar
• Alessi M C, Juhan-Vague I, Kooistra T, DeClerck P J, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line HepG2. Thromb Haemost 1988; 60: 491–4
   PubMed Web of Science ®Google Scholar
• Stiko-Rham A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor 1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067–73
   PubMedGoogle Scholar
• Schneider D J, Nordt T K, Sobel B E. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes 1992; 41: 890–5
   PubMed Web of Science ®Google Scholar
• Schneider D J, Sobel B E. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implication for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA 1991; 88: 9959–63
   PubMed Web of Science ®Google Scholar
• Nordt T K, Schneider D J, Sobel B E. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 1994; 89: 321–30
   PubMed Web of Science ®Google Scholar
• Sironi L, Mussoni L, Prati L, Baldassarre D, Camera M, Banfi C, et al. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol 1966; 16: 89–96
   Google Scholar
• Schneider D J, Sobel B E. Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids. Coron Artery Dis 1996; 7: 813–7
   PubMed Web of Science ®Google Scholar
• Banfi C, Rise P, Mussoni L, Galli C, Tremoli E. Linoleic acid enhances the secretion of plasminogen activator inhibitor type 1 by HepC2 cells. J Lipid Res 1997; 38: 860–9
   PubMed Web of Science ®Google Scholar
• Rikder P M, Vaughan D E, Stampfer M J, Manson J E, Hennekens C H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165–8
   PubMed Web of Science ®Google Scholar
• Thompson S G, Kienast J, Pyke S DM, Haverkate F, van de Loo J CW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635–41
   PubMed Web of Science ®Google Scholar
• Juhan-Vague I, Pyke S DM, Alessi M C, Jespersen J, Haverkate F, Thompson S G. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94: 2057–63
   PubMed Web of Science ®Google Scholar
• Chandler W L, Trimble S L, Loo S C, Mornin D. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood 1990; 76: 930–7
   PubMed Web of Science ®Google Scholar
• Chandler W L, Alessi M C, Aillaud M F, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex. Relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 1997; 96: 761–8
   PubMed Web of Science ®Google Scholar
• Beaumont J L, Carlson L A, Cooper G R, Fejfar Z, Fredrickson D S, Strasser T. Classification of hyperlipidemias and hyper-lipoproteinemias. Bull World Health Organ 1970; 43: 891–15
   PubMed Web of Science ®Google Scholar
• Röschlau P, Bernt E, Gruber W. Enzymatic determination of total cholesterol in serum (in German). Z Klin Chem Klin Biochem 1974; 12: 403–7
   PubMedGoogle Scholar
• Bucolo G, David M. Quantitative determination of serum triglycerides by use of enzymes. Clin Chem 1973; 19: 476–82
   PubMed Web of Science ®Google Scholar
• Warnick G R, Benderson J, Albers J J. Dextran sulfate precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982; 28: 1379–88
   PubMed Web of Science ®Google Scholar
• Friedewald W T, Levy R I, Fredrickson D S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502
   PubMed Web of Science ®Google Scholar
• Lipid Research Clinics Program. Manual of Laboratory Operations. US Department of Health, Education, and Welfare, National Institutes of Health, Lipid Research Clinics Program, I, Washington, DC 1974; 75: 628
   Google Scholar
• Clauss A. A rapid method for the determination of clottable fibrinogen (in German). Acta Haematol 1957; 17: 237–45
   PubMedGoogle Scholar
• Caro J F. Clinical review 26: Insulin resistance in obese and nonobese man. J Clin Endocrinol Metab 1991; 73: 691–5
   PubMed Web of Science ®Google Scholar
• Juhan-Vague I, Alessi M C. Regulation of fibrinolysis in the development of atherothrombosis: role of adipose tissue. Thromb Haemost 1999; 82: 832–6
   PubMed Web of Science ®Google Scholar
• Vague P, Juhan-Vague I, Aillaud M F, Badier C, Ward R, Alessi M C, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250–3
   PubMed Web of Science ®Google Scholar
• Reilly T M, Greenplate G, Timmermans M WM. Tissue plasminogen activator-induced secretion of type-1 plasminogen activator inhibitor in cultured human fibroblasts. Thromb Res 1998; 55: 619–25
   Google Scholar
• Fujii S, Lucore C L, Hopkins W E, Billadello J J, Sobel B E. Induction of synthesis of plasminogen activator inhibitor type-1 by tissue plasminogen activator in human hepatic and endothelial cells. Thromb Haemost 1990; 64: 412–9
   PubMed Web of Science ®Google Scholar
• Emeis J J, van den Eijnden-Scrauwen Y, van den Hoogen C M, dePriester W, Westmuckett A, Lupu F. An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol 1997; 139: 245–56
   PubMed Web of Science ®Google Scholar
• Rosnoblet C, Vischer U M, Gerard R D, Irminger J C, Halban P A, Kruithof E KO. Storage of tissue-type plasminogen activator in Weibel-Palade bodies of human endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 1796–803
   PubMed Web of Science ®Google Scholar
• Booyse F M, Bruce R, Gianturco S H, Bradley W A. Normal but not hypertriglyceridemic very low density lipoprotein induces rapid release of tissue plasminogen activator from cultured human umbilical vein endothelial cells. Semin Thromb Hemost 1988; 14: 175–9
   PubMed Web of Science ®Google Scholar
• Noll G, Luscher T F. Influence of lipoproteins on endothelial function. Thromb Res 1994; 74(Suppl 1)S45–54
   Google Scholar
• Jansson J H, Olofsson B O, Nilsson T K. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993; 88: 2030–4
   PubMed Web of Science ®Google Scholar
• Ridker P M. Endogenous fibrinolytic function and risk of future myocardial infarction and stroke: observations from the Physicians' Health Study. Fibrinolysis Proteolysis 1997; 11: 55–9
   Google Scholar
• Thögersen A M, Jansson J -H, Boman K, Nilsson T, Weinehall K L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241–7
   PubMed Web of Science ®Google Scholar